ReviewThe Lancet. Neurology2008
Current and future uses of neuroimaging for cognitively impaired patients.
Review in The Lancet. Neurology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Thai Guideline for Nuclear Medicine Investigations of Neurocognitive Disorders: Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and Thai Medical Physicist Society Collaboration.Diagnostics (Basel, Switzerland) · 2024Guideline
- Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study.Behavioural neurology · 2015Trial
- Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2008Trial
- rTMS reduces delta and increases theta oscillations in Alzheimer's disease: A visual-evoked and event-related potentials study.CNS neuroscience & therapeutics · 2024Article
- Neural correlates of beneficial effects of young plasma treatment in aged mice: PET-SPM analyses and neuro-behavioural/molecular biological studies.European journal of nuclear medicine and molecular imaging · 2022Article
- PET imaging of neural activity, β-amyloid, and tau in normal brain aging.European journal of nuclear medicine and molecular imaging · 2021Review
- The Role of Perioperative Sleep Disturbance in Postoperative Neurocognitive Disorders.Nature and science of sleep · 2021Review
- Reduced thiamine is a predictor for cognitive impairment of cerebral infarction.Brain and behavior · 2020Article
- Two-decade change in prevalence of cognitive impairment in the UK.European journal of epidemiology · 2019Article
- Dementia spectrum disorders: lessons learnt from decades with PET research.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
- FDDNP-PET Tau Brain Protein Binding Patterns in Military Personnel with Suspected Chronic Traumatic Encephalopathy1.Journal of Alzheimer's disease : JAD · 2018Article
- Neuroimaging in vascular cognitive impairment: a state-of-the-art review.BMC medicine · 2016Review
- Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2015Review
- Imaging biomarkers associated with cognitive decline: a review.Biological psychiatry · 2015Review
- Mild traumatic brain injury and delayed alteration of memory processing.Frontiers in neuroscience · 2015Article
- Effects of rivastigmine and memantine alone and in combination on learning and memory in rats with scopolamine-induced amnesia.Open medicine (Warsaw, Poland) · 2015Article
- Review
- A review of β-amyloid neuroimaging in Alzheimer's disease.Frontiers in neuroscience · 2014Review
- Regional cerebral perfusion in patients with Alzheimer's disease and mild cognitive impairment: effect of APOE epsilon4 allele.Neuroradiology · 2013Article
- PET imaging of neuropathology in tauopathies: progressive supranuclear palsy.Journal of Alzheimer's disease : JAD · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Technological advances have led to greater use of both structural and functional brain imaging to assist with the diagnosis of dementia for the increasing numbers of people with cognitive decline as they age. In current clinical practice, structural imaging (CT or MRI) is used to identify space-occupying lesions and stroke. Functional methods, such as PET scanning of glucose metabolism, could be used to differentiate Alzheimer's disease from frontotemporal dementia, which helps to guide clinicians in symptomatic treatment strategies. New neuroimaging methods that are currently being developed can measure specific neurotransmitter systems, amyloid plaque and tau tangle concentrations, and neuronal integrity and connectivity. Successful co-development of neuroimaging surrogate markers and preventive treatments might eventually lead to so-called brain-check scans for determining risk of cognitive decline, so that physicians can administer disease-modifying medications, vaccines, or other interventions to avoid future cognitive losses and to delay onset of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.